Data / Research funding / Chronic Liver Disease and Cirrhosis
Chronic Liver Disease and Cirrhosis: 1,580 NIH awards ($1.9B) to 309 organizations
1,580 NIH awards ($1.9B) in the NIH spending category Chronic Liver Disease and Cirrhosis, to 309 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,580 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Epidemiology of Diabetes Interventions and Complications (EDIC) Study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $35,015,476 | September 22, 2011 | June 30, 2027 | GUBITOSI-KLUG, ROSE A | reporter.nih.gov |
| University of Arizona Cancer Center - Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $21,155,920 | July 1, 1997 | July 31, 2027 | THEODORESCU, DAN | reporter.nih.gov |
| Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,807,472 | August 1, 2018 | August 31, 2030 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| Center for Cellular Metabolism Research in Oklahoma | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $15,159,612 | February 5, 2021 | January 31, 2027 | XIA, LIJUN | reporter.nih.gov |
| Hepatobiology and Toxicology COBRE | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,863,981 | June 10, 2016 | March 31, 2027 | MCCLAIN, CRAIG J. | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Indiana University Data Coordinating Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $11,773,646 | August 1, 2018 | June 30, 2029 | TU, WANZHU | reporter.nih.gov |
| Mays Cancer Center at UT Health SA | NIH | National Cancer Institute | 2021 to 2025 | $11,193,809 | August 1, 1997 | July 31, 2026 | ZHENG, LEI | reporter.nih.gov |
| Liver Cirrhosis Network: Scientific and Data Coordination Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $10,655,826 | August 28, 2021 | July 31, 2027 | SMITH, ABIGAIL | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2023 to 2025 | $10,038,112 | September 21, 2021 | August 31, 2027 | HOYO, CATHRINE | reporter.nih.gov |
| Childhood Liver Disease Research Network (ChiLDReN) Scientific and Data Coordinating Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $9,404,513 | September 18, 2002 | May 31, 2029 | MAGEE, JOHN C | reporter.nih.gov |
| Data Coordinating Center for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Continuation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $8,663,508 | May 1, 2002 | June 30, 2028 | SHADE, DAVID M | reporter.nih.gov |
| Columbia Diabetes Research Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,800,557 | September 1, 2002 | December 31, 2027 | PAJVANI, UTPAL | reporter.nih.gov |
| A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,767,541 | April 15, 2021 | March 31, 2027 | SCHAUBEL, DOUGLAS EARL | reporter.nih.gov |
| Subcutaneous Drug Development for Portal Hypertension Ascites | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,758,500 | September 22, 2014 | July 31, 2027 | CASTILLO, GERARDO M. | reporter.nih.gov |
| Novel therapy for alcoholic liver disease-associated hepatorenal syndrome | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $6,485,223 | September 25, 2021 | August 31, 2027 | SUBRAMANIAN, MANI | reporter.nih.gov |
| The spectrum of cognitive impairment including Alzheimer’s Disease and Related Dementias after liver transplantation | NIH | National Institute on Aging | 2021 to 2025 | $6,330,805 | June 15, 2018 | May 31, 2028 | LAI, JENNIFER C. | reporter.nih.gov |
| Ancillary Studies of NAFLD and NASH in HIV infected Adults | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $6,132,391 | March 21, 2020 | January 31, 2026 | CHALASANI, NAGA P | reporter.nih.gov |
| Rational design and efficacy testing of vaccines against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,737,237 | May 5, 2022 | April 30, 2027 | FUERST, THOMAS R | reporter.nih.gov |
| Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $4,780,391 | June 1, 2023 | March 31, 2028 | MAHER, JACQUELYN J. | reporter.nih.gov |
| Targeting hepatic stellate cell metabolism to treat steatotic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,674,973 | April 1, 2015 | August 31, 2029 | FINCK, BRIAN N | reporter.nih.gov |
| Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $4,589,716 | September 1, 2019 | August 31, 2024 | KIZER, JORGE R | reporter.nih.gov |
| Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $4,582,323 | September 20, 2018 | July 31, 2024 | STAHL, ANDREAS | reporter.nih.gov |
| Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,371,481 | September 30, 2018 | July 31, 2025 | HAVENS, JENNIFER R | reporter.nih.gov |
| A novel diagnostic Kit for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $3,993,675 | September 1, 2012 | August 31, 2025 | LU, XUANYONG | reporter.nih.gov |
| Next-generation human liver gene therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,896,814 | September 30, 2021 | June 30, 2027 | WILLENBRING, HOLGER | reporter.nih.gov |
| Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules | NIH | National Cancer Institute | 2023 to 2025 | $3,858,633 | September 19, 2023 | August 31, 2028 | SINGAL, AMIT | reporter.nih.gov |
| A Rhesus Macaque Model of HIV and HBV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,842,980 | March 20, 2021 | February 28, 2026 | BURWITZ, BENJAMIN J | reporter.nih.gov |
| The UCLA Center in Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,825,539 | September 17, 2018 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Clinical Validation Center for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,730,583 | August 3, 2022 | July 31, 2027 | SINGAL, AMIT | reporter.nih.gov |
| Pathogenesis of youth onset pre-diabetes and Type 2 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,716,431 | September 22, 2016 | July 31, 2026 | CAPRIO, SONIA | reporter.nih.gov |
| HAWAII CLINICAL RESEARCH NETWORK FOR HEALTH EQUITY | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $3,711,764 | September 24, 2022 | November 30, 2027 | SHIKUMA, CECILIA M. | reporter.nih.gov |
| Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,678,371 | September 7, 2021 | August 31, 2026 | YUAN, JIAN-MIN | reporter.nih.gov |
| Trial of Statins for Chemoprevention in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,646,155 | September 1, 2021 | August 31, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Estrogen Administration for the Treatment of NASH in Postmenopausal Women | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,638,994 | August 1, 2021 | May 31, 2027 | MILLER, KAREN K | reporter.nih.gov |
| Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,618,437 | September 1, 2016 | June 30, 2026 | COOPER, STEWART | reporter.nih.gov |
| NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,593,236 | February 7, 2022 | January 31, 2027 | RIBEIRO, RUY M | reporter.nih.gov |
| Interactions between neutrophils and cholangiocytes in alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,548,231 | September 25, 2021 | June 30, 2027 | NATHANSON, MICHAEL H | reporter.nih.gov |
| Risk Stratification for and Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,531,567 | September 13, 2018 | August 31, 2028 | KANWAL, FASIHA | reporter.nih.gov |
| Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,517,747 | June 1, 2021 | February 28, 2027 | KHALILI, MANDANA | reporter.nih.gov |
| Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,515,317 | August 1, 2006 | July 31, 2026 | KAY, MARK A | reporter.nih.gov |
| Clinical Center for Cholestatic Liver Disease in Children | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,505,921 | September 15, 2002 | May 31, 2029 | MIETHKE, ALEXANDER | reporter.nih.gov |
| Abbreviated MRI for HCC screening in cirrhotic patients | NIH | National Cancer Institute | 2021 to 2024 | $3,461,079 | June 19, 2020 | May 31, 2026 | TAOULI, BACHIR | reporter.nih.gov |
| Clinical Research on Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,430,513 | September 15, 2002 | June 30, 2027 | LOOMBA, ROHIT | reporter.nih.gov |
| Human Genetic determinants of HBV recovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,412,348 | September 30, 1999 | December 31, 2026 | THOMAS, DAVID L | reporter.nih.gov |
| Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,411,692 | September 24, 2025 | August 31, 2030 | NAGGIE, SUSANNA | reporter.nih.gov |
| Evaluation of a community-based education, navigation, and support (CENS) intervention to reduce opioid-related harms among military veterans | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,379,762 | September 30, 2021 | July 31, 2027 | BENNETT, ALEXANDER S | reporter.nih.gov |
| Liquid biopsy and radiomics for liver cancer surveillance | NIH | National Cancer Institute | 2023 to 2025 | $3,338,250 | September 19, 2023 | August 31, 2028 | TAOULI, BACHIR | reporter.nih.gov |
| Immunologic correlates of functional cure of HBV with immune checkpoint blockade | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,338,136 | May 22, 2020 | April 30, 2026 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| A geospatial analysis of hotspots and targeted injection settings pilot intervention for HIV prevention among people who inject drugs in Baltimore, Maryland | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,292,995 | July 1, 2020 | May 31, 2027 | LATKIN, CARL A | reporter.nih.gov |
| A smartphone-enabled point-of-care HCV Ag diagnostic using catalytic nanoparticles and AI-enhanced image processing | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $3,284,055 | September 9, 2022 | June 30, 2027 | SHAFIEE, HADI | reporter.nih.gov |
| Prevention of Pediatric NAFLD in Hispanic Children | NIH | National Institute of Nursing Research | 2021 to 2025 | $3,279,874 | April 5, 2021 | January 31, 2026 | WELSH, JEAN A. | reporter.nih.gov |
| Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,276,651 | September 23, 2021 | July 31, 2027 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Stable therapy in Pompe disease through genome editing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,274,213 | August 1, 2021 | July 31, 2026 | KOEBERL, DWIGHT D | reporter.nih.gov |
| IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,273,154 | August 1, 2022 | July 31, 2027 | KOLTSOVA, EKATERINA | reporter.nih.gov |
| Longitudinal Study of Early NAFLD Progression and the Gut Microbiome in Asian Americans, Native Hawaiians and Whites | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,263,901 | September 26, 2022 | June 30, 2027 | LIM, UNHEE | reporter.nih.gov |
| Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,258,965 | September 6, 2021 | July 31, 2027 | KHALILI, MANDANA | reporter.nih.gov |
| Role of Neutrophils in the Pathogenesis of Cholangiopathies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,233,421 | September 1, 2025 | August 31, 2029 | STRAZZABOSCO, MARIO | reporter.nih.gov |
| Examine Individual and Clinical Factors Affecting Liver Disease Management | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,219,854 | September 15, 2022 | May 31, 2027 | MA, GRACE X. | reporter.nih.gov |
| Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,197,232 | January 18, 2021 | December 31, 2026 | ZHU, YAZHEN | reporter.nih.gov |
| Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,186,484 | August 1, 2022 | July 31, 2027 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Collaborative Integration of HCV Molecular Virology and Mathematical Modeling | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,185,361 | August 1, 2010 | May 31, 2027 | UPRICHARD, SUSAN L. | reporter.nih.gov |
| Intestinal proteases in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $3,182,397 | September 20, 2025 | August 31, 2029 | SCHNABL, BERND G. | reporter.nih.gov |
| Novel macrophage mediated signals regulate the immunoregulatory environment of the neonatal liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,176,680 | September 15, 2025 | September 14, 2029 | NIJAGAL, AMAR | reporter.nih.gov |
| CTRP and Metabolic Control | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,168,077 | July 15, 2010 | June 30, 2028 | WONG, GUANG WILLIAM | reporter.nih.gov |
| Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,156,556 | February 10, 2020 | April 30, 2030 | RICE, CHARLES M | reporter.nih.gov |
| Extracellular vesicle cargo and risk of NAFLD and NASH in U.S. youth | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,153,279 | April 15, 2022 | February 28, 2027 | DISTEFANO, JOHANNA K | reporter.nih.gov |
| Epigenetics of human Hepatic Stellate Cells (HSCs) in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,103,795 | May 15, 2014 | August 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| Modeling diabetes using an integrated plate system | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $3,092,998 | September 20, 2018 | July 31, 2024 | WELLS, JAMES M | reporter.nih.gov |
| LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes | NIH | National Institute on Aging | 2021 to 2025 | $3,057,044 | September 30, 2021 | May 31, 2027 | LADNER, DANIELA P | reporter.nih.gov |
| RNA modifications in apolipoprotein regulation by environmental exposures | NIH | National Institute of Environmental Health Sciences | 2025 | $3,051,769 | September 11, 2025 | August 31, 2029 | KLINGE, CAROLYN M. | reporter.nih.gov |
| The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,045,888 | September 30, 2020 | August 31, 2025 | IRVIN, RISHA | reporter.nih.gov |
| GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,034,670 | June 5, 2018 | March 31, 2025 | NAKAAR, VALERIAN | reporter.nih.gov |
| Dissecting the pathogenesis and outcomes of PSC using multi-omics by studying the exposome and genome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $3,027,125 | September 1, 2018 | July 31, 2025 | LAZARIDIS, KONSTANTINOS N | reporter.nih.gov |
| A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment among Young Adult People who Inject Drugs | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,017,588 | June 1, 2022 | March 31, 2027 | MORRIS, MEGHAN D | reporter.nih.gov |
| HAWAII CLINICAL RESEARCH NETWORK FOR HEALTH EQUITY | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2023 | $3,015,250 | September 24, 2022 | June 30, 2024 | SHIKUMA, CECILIA M. | reporter.nih.gov |
| Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,010,755 | March 18, 2021 | February 28, 2027 | KANWAL, FASIHA | reporter.nih.gov |
| Generating Exogenic Organs for Transplantation without the Use of Immunosuppression | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,005,890 | September 21, 2022 | July 31, 2027 | STEER, CLIFFORD JOHN | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Regulation of mitochondrial health in mammalian livers. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,999,512 | September 1, 2025 | August 31, 2029 | MISHRA, PRASHANT | reporter.nih.gov |
| Targeting hepatitis B virus cccDNA during HBV/HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,993,820 | August 20, 2024 | July 31, 2029 | PLOSS, ALEXANDER | reporter.nih.gov |
| Molecular Magnetic Resonance of Hepatic Fibrogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,974,604 | July 3, 2019 | March 31, 2028 | CARAVAN, PETER D | reporter.nih.gov |
| Translational control underlies nutrition and metabolism in health and disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,971,227 | September 4, 2025 | August 31, 2029 | RUGGERO, DAVIDE | reporter.nih.gov |
| Photoabsorbing bioinks for expanding 3D printed human liver in situ | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,967,973 | September 21, 2021 | May 31, 2026 | STEVENS, KELLY R | reporter.nih.gov |
| Ethanol Effects on the Transcriptional Regulatory Network in Liver Regeneration | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,943,903 | September 30, 2009 | July 31, 2027 | SRIVASTAVA, ANKITA | reporter.nih.gov |
| Novel IL-23 inhibitor for the treatment of alcohol associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,935,798 | September 20, 2020 | August 31, 2025 | LOOMBA, ROHIT | reporter.nih.gov |
| Moderately CHO-restricted diet as treatment targeting improvement in hepatic lipid and insulin sensitivity in adolescents with NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,928,802 | May 5, 2021 | July 31, 2026 | GOSS, AMY MISKIMON | reporter.nih.gov |
| PNPLA3 in Susceptibility and Resistance to Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,920,007 | August 1, 2011 | July 31, 2027 | HOBBS, HELEN HASKELL | reporter.nih.gov |
| Roles of Neogenin and Matriptase-2 in Iron Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,896,213 | February 1, 2015 | July 31, 2028 | ZHANG, AN-SHENG | reporter.nih.gov |
| Non-invasive etiology-adjusted precision liver cancer risk prediction | NIH | National Cancer Institute | 2025 | $2,876,456 | August 5, 2025 | July 31, 2029 | HOSHIDA, YUJIN | reporter.nih.gov |
| Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,869,940 | September 23, 2021 | July 31, 2027 | BROWN, ROBERT S | reporter.nih.gov |
| Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,861,646 | January 1, 2017 | December 31, 2024 | GINSBERG, HENRY N | reporter.nih.gov |
| Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection | NIH | National Institute on Aging | 2021 to 2023 | $2,851,326 | May 1, 2019 | January 31, 2025 | TRIANT, VIRGINIA ATHENA | reporter.nih.gov |
| Clinical Resource for Alcoholic Hepatitis Inestigation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,850,908 | August 1, 2016 | April 30, 2027 | SUN, ZHAOLI | reporter.nih.gov |
| Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,842,189 | November 1, 2021 | October 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,836,440 | July 15, 2020 | June 30, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Significance and mechanisms of hepatic ChREBPα induction via post-translational modifications in diet-induced NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,830,469 | April 1, 2014 | May 31, 2027 | YIN, LEI | reporter.nih.gov |
| Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,802,377 | February 15, 2020 | January 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Selective mTORC1 inhibition to prevent and treat NAFLD and NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,795,850 | July 15, 2016 | May 31, 2026 | ARANY, ZOLTAN P | reporter.nih.gov |
| Cognitive Function, Self-Management, and Health Outcomes among Liver Transplant Recipients: the LivCog Cohort | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,788,955 | May 4, 2022 | February 28, 2027 | SERPER, MARINA | reporter.nih.gov |
| Metabolic Markers and Predictors of Childhood Obesity | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,780,011 | June 1, 1991 | February 28, 2026 | CAPRIO, SONIA | reporter.nih.gov |
| Novel Biomarkers for Post-Liver Transplant NASH Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,777,764 | July 18, 2022 | May 31, 2027 | ARTEEL, GAVIN E | reporter.nih.gov |
| RNA modification in cardiometabolic disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,776,155 | August 1, 2021 | May 31, 2026 | SALLAM, TAMER | reporter.nih.gov |
| Statin Therapy for patients with compensated Cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,767,121 | September 22, 2021 | July 31, 2027 | TAPPER, ELLIOT | reporter.nih.gov |
| Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant: The TEST Trial | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,750,911 | May 19, 2022 | April 30, 2027 | SERPER, MARINA | reporter.nih.gov |
| Metabolic impact of FGF-21 in adipose tissue and liver of PLWH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,750,246 | September 10, 2020 | June 30, 2026 | LAKE, JORDAN E | reporter.nih.gov |
| Defining mechanisms of extracellular succinate regulation over metabolic tissue function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,748,905 | September 13, 2019 | June 30, 2028 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| Determining how chronic ETOH influences the regenerative activities of hepatocyte subpopulations | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,741,497 | August 1, 2021 | April 30, 2026 | ZHU, HAO | reporter.nih.gov |
| Association between pre-diagnosis hepatic fat infiltration and risk of liver metastasis and mortality in a large cohort of stage I-III colorectal cancer survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,716,606 | September 23, 2022 | August 31, 2027 | GIOVANNUCCI, EDWARD | reporter.nih.gov |
| Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,715,093 | April 15, 2022 | March 31, 2027 | NORTON, LUKE | reporter.nih.gov |
| Gene therapy for glycogen storage disease type III | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,697,948 | April 1, 2022 | March 31, 2027 | SUN, BAODONG | reporter.nih.gov |
| Covalent Chemistry on Nanosubstrates Enables Molecular Analysis of Purified Extracellular Vesicles in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $2,695,903 | July 7, 2020 | June 30, 2026 | TSENG, HSIAN-RONG | reporter.nih.gov |
| Integrative Polygenic Genetic Studies of Non-alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,693,501 | April 1, 2022 | March 31, 2027 | SPELIOTES, ELIZABETH K | reporter.nih.gov |
| Jagged-Notch signaling in NASH/fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,685,447 | February 15, 2019 | June 30, 2028 | PAJVANI, UTPAL | reporter.nih.gov |
| Advanced Fibrosis Detection and a Predictive Diagnostic Model for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,682,628 | September 1, 2025 | August 31, 2029 | SCHREINER, ANDREW DAVID | reporter.nih.gov |
| Spinal cord injury causes liver pathology and metabolic dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,668,295 | April 1, 2021 | March 31, 2027 | MCTIGUE, DANA M | reporter.nih.gov |
| Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $2,655,656 | January 1, 2021 | November 30, 2026 | SETIAWAN, VERONICA WENDY | reporter.nih.gov |
| Hereditary Genetics of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,655,540 | February 1, 2022 | June 30, 2027 | WANGENSTEEN, KIRK J | reporter.nih.gov |
| Deciphering the Mechanisms by which Long Chain Fatty Acid Oxidation Influences Spatial Microvesicular Steatosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,651,504 | September 5, 2025 | September 4, 2029 | HELSLEY, ROBERT NATHANIEL | reporter.nih.gov |
| Natural history, risk prediction and cost of cirrhosis in insured Americans. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,651,386 | February 1, 2022 | May 31, 2026 | LADNER, DANIELA P | reporter.nih.gov |
| Early Detection of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,637,669 | June 3, 2016 | February 28, 2027 | BERETTA, LAURA | reporter.nih.gov |
| Discovery of novel therapeutic targets for NASH through deep phenotyping of human knockouts and mechanistic studies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,636,860 | September 15, 2022 | June 30, 2026 | TABAS, IRA A | reporter.nih.gov |
| Identification and Characterization of Loci Associated with Non-alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,634,402 | April 1, 2021 | March 31, 2026 | ALLRED, NICHOLETTE D. | reporter.nih.gov |
| Altered Lipid Droplet Trafficking: Role in Alcoholic Fatty Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,633,095 | August 10, 2011 | June 30, 2027 | CASEY, CAROL A. | reporter.nih.gov |
| Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survival | NIH | National Cancer Institute | 2022 to 2025 | $2,628,801 | June 2, 2022 | May 31, 2027 | SONG, MINGYANG | reporter.nih.gov |
| Cutaneous biomarkers of pediatric non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,615,502 | June 17, 2022 | March 31, 2027 | MOUZAKI, MARIALENA | reporter.nih.gov |
| Regulation of Metabolism by FGF21 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,614,390 | July 15, 2015 | June 30, 2028 | POTTHOFF, MATTHEW JOSEPH | reporter.nih.gov |
| Racial and Ethnic Disparities in Hepatocellular Carcinoma Surveillance Among Patients with Cirrhosis Across Five Safety Net Organizations | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,613,442 | December 22, 2021 | November 30, 2026 | WONG, ROBERT JOHN | reporter.nih.gov |
| Systems Genetics Dissection of Non-alcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,612,818 | July 1, 2019 | March 31, 2028 | LUSIS, ALDONS JAKE | reporter.nih.gov |
| Pathogenesis of Primary Biliary Cholangitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,607,525 | December 21, 2020 | November 30, 2025 | LAZARIDIS, KONSTANTINOS N | reporter.nih.gov |
| Harnessing macrophage lysosomal lipid metabolism in obesity-associated diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,605,827 | July 4, 2022 | June 30, 2026 | SCHILLING, JOEL DAVID | reporter.nih.gov |
| The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,604,074 | March 1, 2023 | February 29, 2028 | SIMON, TRACEY | reporter.nih.gov |
| Bio-Psycho-Social Drivers of Disparities in Liver Disease Progression among Korean Americans with Hepatitis B Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,557,384 | April 12, 2021 | March 31, 2026 | JUON, HEE-SOON | reporter.nih.gov |
| Functions of vitamin E and the tocopherol transfer protein | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,551,370 | April 20, 2021 | December 31, 2025 | MANOR, DANNY | reporter.nih.gov |
| First-in-human study of a potent anti-HBsAg neutralizing antibody | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,534,231 | March 20, 2023 | February 28, 2027 | CASKEY, MARINA | reporter.nih.gov |
| Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC | NIH | National Cancer Institute | 2021 to 2025 | $2,533,680 | July 20, 2021 | June 30, 2026 | SCHWABE, ROBERT F. | reporter.nih.gov |
| ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,517,485 | April 1, 2021 | March 31, 2027 | STEVENSON, HEATHER L | reporter.nih.gov |
| Intestinally restricted LXR agonism in ameliorating liver failure in short gut syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,504,630 | March 1, 2019 | February 28, 2029 | RANDOLPH, GWENDALYN J | reporter.nih.gov |
| Role and regulation of beta-catenin in cholestatic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,493,803 | July 1, 2015 | July 31, 2027 | NEJAK-BOWEN, KARI N | reporter.nih.gov |
| Understanding human antibody responses to chronic viral hepatitis C | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,488,538 | January 17, 2022 | December 31, 2026 | LAW, MANSUN | reporter.nih.gov |
| TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $2,484,849 | September 10, 2020 | August 31, 2025 | RAMUNAS, JOHN | reporter.nih.gov |
| The role of AEG-1 in NASH and NASH-HCC | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,484,379 | July 25, 2016 | December 31, 2025 | SARKAR, DEVANAND | reporter.nih.gov |
| Quantification of Liver Fibrosis with MRI and Deep Learning | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,480,232 | April 1, 2021 | December 31, 2025 | HE, LILI | reporter.nih.gov |
| HBV Capsid Effectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,475,992 | June 1, 2017 | February 28, 2027 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Preservation of DCD Allograft Integrity for Liver Transplantation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,457,892 | January 13, 2020 | November 30, 2025 | BLACK, SYLVESTER M | reporter.nih.gov |
| Molecular Magnetic Resonance Imaging of Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,451,935 | August 1, 2019 | November 30, 2029 | GALE, ERIC MICHAEL | reporter.nih.gov |
| Sex-Specific Risk of Metabolic and Cardiovascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,450,619 | June 15, 2019 | June 30, 2025 | STAFFORD, JOHN MICHAEL | reporter.nih.gov |
| Dissecting the Role of Arachidonic Acid Metabolic Pathways Involved in Resolution Versus Progression of PM-Induced Cardiometabolic Toxicity | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,445,294 | February 11, 2022 | November 30, 2026 | ARAUJO, JESUS ANTONIO | reporter.nih.gov |
| New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,444,033 | March 10, 2022 | February 28, 2027 | OSNA, NATALIA ALEKSANDR | reporter.nih.gov |
| Fully Automated High-Throughput Quantitative MRI of the Liver | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,442,717 | April 8, 2022 | December 31, 2026 | REEDER, SCOTT B. | reporter.nih.gov |
| Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,437,500 | May 1, 2019 | April 30, 2025 | ALBARRACIN, DOLORES | reporter.nih.gov |
| Blocking hepatocyte senescence as a novel therapeutic strategy for chronic liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,436,055 | September 30, 2021 | August 31, 2026 | OERTEL, MICHAEL | reporter.nih.gov |
| Integrative Physiology of Thyroid Hormone Receptors and Nuclear Receptor Corepressors | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,435,612 | June 1, 1991 | April 30, 2029 | LAZAR, MITCHELL A. | reporter.nih.gov |
| Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Clinical Center-Cleveland site | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,432,868 | June 15, 2002 | June 30, 2027 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Colorado Center of Childhood Liver Disease ResearchNetwork | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,425,994 | September 15, 2002 | May 31, 2029 | SOKOL, RONALD J. | reporter.nih.gov |
| Developing Methods for Precise, Safe and Target-location Specific Histotripsy of Liver Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,424,900 | September 23, 2021 | August 31, 2026 | ZIEMLEWICZ, TIMOTHY J | reporter.nih.gov |
| YAP signaling in the pathogenesis of NAFLD in people living with HIV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,422,019 | September 26, 2023 | July 31, 2028 | CHUNG, RAYMOND T | reporter.nih.gov |
| The Role of Portal Fibroblasts in Cholestatic Liver Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,413,733 | September 15, 2014 | March 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| ATP Binding Cassette Transporters in Health and Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,408,231 | April 9, 2021 | January 31, 2025 | TARLING, ELIZABETH JOANNA | reporter.nih.gov |
| Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,403,276 | June 1, 2016 | January 31, 2027 | HORNER, STACY MICHELLE | reporter.nih.gov |
| Atlanta Center for the Childhood Liver Disease Research Network (ChiLDReN) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,403,001 | March 7, 2005 | May 31, 2024 | KARPEN, SAUL J. | reporter.nih.gov |
| Longitudinal integration of environmental exposures, omics, and childhood NAFLD (LEON) Study | NIH | National Human Genome Research Institute | 2023 to 2025 | $2,401,345 | September 12, 2023 | May 31, 2028 | CHATZI, VAIA LIDA | reporter.nih.gov |
| Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | NIH | National Cancer Institute | 2021 to 2024 | $2,400,000 | August 16, 2021 | August 31, 2025 | LAM, SIU KIT | reporter.nih.gov |
| Biomarkers of Alcoholic Hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,386,096 | June 1, 2020 | May 31, 2026 | ARTEEL, GAVIN E | reporter.nih.gov |
| The mTOR-ETV5 signaling in gastric X/A like cells and its role in hepatic lipid metabolism and steatosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,377,177 | July 1, 2021 | March 31, 2026 | SEELEY, RANDY J | reporter.nih.gov |
| Lymphatics in the liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,371,957 | July 1, 2022 | June 30, 2027 | IWAKIRI, YASUKO | reporter.nih.gov |
| The Role of the Intestinal Mycobiome in Alcoholic Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,368,040 | June 1, 2017 | March 31, 2027 | SCHNABL, BERND G. | reporter.nih.gov |
| Quantitative MRI and Deep Learning Technologies for Classification of NAFLD | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,364,000 | August 1, 2022 | April 30, 2027 | WU, HOLDEN H | reporter.nih.gov |
| Kentucky Outreach Service Kiosk (KyOSK): Reducing Overdose, Hepatitis C, and Other Drug-related Risks in Rural Appalachia through Health Kiosks | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,359,307 | August 15, 2022 | June 30, 2027 | YOUNG, APRIL MARIE | reporter.nih.gov |
| The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,345,542 | August 1, 2022 | November 30, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,342,707 | April 1, 2013 | April 30, 2026 | FORSBERG, FLEMMING | reporter.nih.gov |
| Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,331,243 | August 1, 2020 | June 30, 2025 | SHAPIRO, MARTIN F. | reporter.nih.gov |
| Heat shock protein 90 in alcoholic liver disease: targeting macrophage Function | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,330,377 | August 1, 2009 | June 30, 2027 | MANDREKAR, PRANOTI | reporter.nih.gov |
| Aldehydes in Alcohol-Induced Organ Injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,325,195 | September 30, 2010 | February 29, 2028 | ZHOU, ZHANXIANG | reporter.nih.gov |
| Adipsin in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,324,625 | July 1, 2022 | April 30, 2027 | PAJVANI, UTPAL | reporter.nih.gov |
| Hepatocyte-derived extracellular vesicles in alcoholic liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,324,384 | July 1, 2020 | March 31, 2026 | FELDSTEIN, ARIEL | reporter.nih.gov |
| The role of IL-17 signaling in alcohol-induced HCC | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,322,600 | August 6, 2021 | May 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| Intestinal Resection Associated Liver Injury and Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,314,904 | September 30, 2021 | August 31, 2025 | WARNER, BRAD WAYNE | reporter.nih.gov |
| Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,310,512 | September 15, 2022 | June 30, 2027 | SANYAL, ARUN J | reporter.nih.gov |
| A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,306,928 | July 15, 2020 | June 30, 2026 | TAYLOR, D. LANSING | reporter.nih.gov |
| Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,306,170 | July 1, 2022 | April 30, 2027 | GOUON-EVANS, VALERIE B | reporter.nih.gov |
| Fecal microbiota transplant for Alcohol-Associated Cirrhosis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,300,878 | September 12, 2022 | August 31, 2027 | BAJAJ, JASMOHAN S | reporter.nih.gov |
| TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,299,997 | September 22, 2022 | August 31, 2025 | MYERS, ROBERT PAUL | reporter.nih.gov |
| DISSECTING THE LINK BETWEEN UREAGENESIS AND HEPATIC GLYCOGEN METABOLISM | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,297,784 | February 15, 2021 | January 31, 2027 | BURRAGE, LINDSAY C | reporter.nih.gov |
| Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,297,570 | August 1, 2021 | May 31, 2026 | MIMCHE, PATRICE | reporter.nih.gov |
| Maternal Obesity and Pediatric NAFLD: Fetal Origins and Long-term outcomes in Non Human Primates | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,294,587 | September 30, 2021 | July 31, 2025 | FRIEDMAN, JACOB E | reporter.nih.gov |
| Mitochondrial depolarization, mitophagy, and mitochondrial DAMPs in ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,289,684 | August 1, 2018 | June 30, 2028 | ZHONG, ZHI | reporter.nih.gov |
| HuR/HIF – SIRT1 Signaling Axis in Liver Transplant Rejuvenation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,287,369 | April 1, 2003 | March 31, 2027 | KUPIEC-WEGLINSKI, JERZY W | reporter.nih.gov |
| Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,286,418 | July 1, 2024 | May 31, 2029 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| Rip Proteins in Innate Immune Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,272,136 | December 15, 2008 | August 31, 2025 | KELLIHER, MICHELLE ALICE | reporter.nih.gov |
| Evaluation of a persuasive health communication intervention designed to increase HIV/HCV screening among emergency departments patients who currently, formerly or never injected drugs | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,264,864 | September 30, 2022 | July 31, 2027 | MERCHANT, ROLAND C | reporter.nih.gov |
| Reverse-engineering precision liver cancer chemoprevention | NIH | National Cancer Institute | 2021 to 2023 | $2,262,334 | September 23, 2019 | August 31, 2025 | HOSHIDA, YUJIN | reporter.nih.gov |
| Phosphatidylinositol Metabolism and Trafficking in Atherosclerosis and Inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,257,637 | April 1, 2020 | June 30, 2028 | GULSHAN, KAILASH | reporter.nih.gov |
| Intermountain West Clinical Center for a Childhood Liver Disease Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,255,217 | August 20, 2014 | May 31, 2029 | GUTHERY, STEPHEN L | reporter.nih.gov |
| HDAC1 as a nutrient sensor in the development and progression of NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,254,125 | June 3, 2022 | March 31, 2027 | SHI, HANG | reporter.nih.gov |
| Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,252,988 | February 12, 2021 | January 31, 2026 | WAJAPEYEE, NARENDRA | reporter.nih.gov |
| Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,251,770 | September 1, 2023 | June 30, 2027 | FALLON, MICHAEL B | reporter.nih.gov |
| Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,248,119 | September 22, 2021 | June 30, 2027 | GOBEJISHVILI, LEILA | reporter.nih.gov |
| Mechanisms of hepatitis B virus cccDNA formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,246,607 | May 15, 2020 | April 30, 2025 | PLOSS, ALEXANDER | reporter.nih.gov |
| Control of Lipogenesis and Hepatic Steatosis by Caspase-2 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,246,301 | March 15, 2019 | November 30, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| Fibrogenesis Targeted Manganese Based MRI Contrast Agent | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,239,969 | September 15, 2022 | August 31, 2025 | HOFFMAN, VERA | reporter.nih.gov |
| Epigenetic Regulation of Mitochondrial Homeostasis and Energy Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,238,787 | September 21, 2019 | June 30, 2027 | YANG, QIN | reporter.nih.gov |
| Integrated Care for Addiction, HIV and HCV Research and Education (ICAHRE) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,234,611 | July 1, 2017 | June 30, 2027 | STEIN, MICHAEL D | reporter.nih.gov |
| Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,229,932 | April 1, 2021 | December 31, 2025 | REEDER, SCOTT B. | reporter.nih.gov |
| New insights into the functional diversity of the hepatic antiviral T cell response during hepacivirus infection in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,227,294 | June 1, 2022 | May 31, 2027 | BILLERBECK, EVA | reporter.nih.gov |
| Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,223,594 | August 20, 2021 | June 30, 2027 | REMISZEWSKI, STACY | reporter.nih.gov |
| Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,223,387 | September 25, 2020 | July 31, 2025 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Genetic Regulation of Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,221,739 | June 8, 2021 | March 31, 2026 | MEDINA, MARISA WONG | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2021 to 2022 | $2,219,249 | September 21, 2021 | August 31, 2023 | HOYO, CATHRINE | reporter.nih.gov |
| Understanding the metabolic pathology of pediatric obesity and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,218,267 | April 22, 2022 | January 31, 2027 | SHORT, KEVIN R. | reporter.nih.gov |
| Advancing 3D optical body surface scan technology to assess physiological and psychological effects in highly obese population | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,213,224 | September 1, 2021 | August 31, 2025 | HAHN, JAMES K | reporter.nih.gov |
| Investigating the role of frailty on outcomes in acutely ill patients with cirrhosis undergoing liver transplantation in the acute care setting | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,213,082 | July 15, 2023 | April 30, 2028 | LAI, JENNIFER C. | reporter.nih.gov |
| Mechanisms of Hepadnavirus Assembly and Replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,212,330 | February 15, 1999 | August 31, 2028 | HU, JIANMING | reporter.nih.gov |
| Systemic immunoregulatory consequences of bacterial translocation during health and disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,209,196 | September 21, 2021 | June 30, 2026 | MEISEL, MARLIES | reporter.nih.gov |
| Ex-vivo bioengineered technology to unravel dysfunction due to non-alcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,201,102 | July 1, 2023 | April 30, 2027 | WERTHEIM, JASON A | reporter.nih.gov |
| Role of heat shock transcription factor HSF1 in tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,193,704 | July 1, 1996 | January 31, 2027 | MIVECHI, NAHID F | reporter.nih.gov |
| Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,193,363 | May 1, 2021 | April 30, 2027 | BIDDINGER, SUDHA B | reporter.nih.gov |
| Acute Imposition of Fontan Physiology in The Single Ventricle Patient: Effects on Fibrosis, Function and Drug Intervention | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,190,858 | July 1, 2020 | June 30, 2026 | FOGEL, MARK A | reporter.nih.gov |
| HBV-specific T cell immunity in HBV/HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,189,677 | August 1, 2025 | July 31, 2028 | VINIKOOR, MICHAEL JEFFREY | reporter.nih.gov |
| Sterile inflammation and pyroptotic cell death in liver fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,186,355 | March 1, 2017 | May 31, 2028 | HOFFMAN, HAROLD M | reporter.nih.gov |
| RECK regulation of NASH and fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,185,559 | May 15, 2022 | April 30, 2027 | RECTOR, RANDY SCOTT | reporter.nih.gov |
| Deciphering Epithelial Signals in the Liver to Drive Inflammation and Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,182,945 | July 1, 2021 | June 30, 2026 | YIMLAMAI, DEAN | reporter.nih.gov |
| Lipotoxicity and Liver Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,182,776 | April 15, 2020 | February 29, 2028 | IBRAHIM, SAMAR | reporter.nih.gov |
| Therapeutic Mitochondrial Uncouplers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,181,641 | May 1, 2021 | December 31, 2025 | SANTOS, WEBSTER L | reporter.nih.gov |
| Multi-omics for obesity-associated liver disease in a high-risk population cohort | NIH | National Cancer Institute | 2023 to 2025 | $2,178,680 | September 1, 2023 | August 31, 2028 | MCCORMICK, JOSEPH | reporter.nih.gov |
| Understanding the Multilevel Drivers of Liver Cancer Disparities | NIH | National Cancer Institute | 2021 to 2023 | $2,174,412 | August 16, 2019 | July 31, 2025 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Integrative Liver Cell Core | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,169,055 | June 15, 2001 | May 31, 2027 | TSUKAMOTO, HIDEKAZU | reporter.nih.gov |
| Impaired VLDL secretion in progression of NAFLD and NASH in mice and humans | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,167,149 | July 16, 2019 | June 30, 2028 | DAVIDSON, NICHOLAS O. | reporter.nih.gov |
| Exosomal biomarkers for the early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $2,166,339 | August 8, 2023 | July 31, 2028 | GOEL, AJAY | reporter.nih.gov |
| MicroRNAs in Alcoholic Liver Disease Administrative Supplement | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $2,165,347 | September 10, 2011 | July 31, 2024 | SZABO, GYONGYI | reporter.nih.gov |
| Long-Acting, Short-Residing Nanochelators for Iron Overload Therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,154,309 | January 1, 2023 | December 31, 2026 | CHOI, HAK SOO | reporter.nih.gov |
| Dysregulated neutrophil subpopulations as a driving mechanism of liver and gastrointestinal disease in HIV-1-infected individuals | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,145,951 | July 1, 2023 | April 30, 2028 | HEL, ZDENEK | reporter.nih.gov |
| Action of Lipolytic Enzymes | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,144,258 | January 1, 2021 | May 31, 2026 | DENNIS, EDWARD A | reporter.nih.gov |
| Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $2,139,998 | September 11, 2017 | August 31, 2024 | BLITZER, JEREMY | reporter.nih.gov |
| The Saint Louis University Component of the NASH Clinical Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,135,402 | May 20, 2002 | June 30, 2027 | NEUSCHWANDER-TETRI, BRENT A | reporter.nih.gov |
| Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,132,242 | January 19, 2021 | October 31, 2026 | CLARKE, JOHN DANIEL | reporter.nih.gov |
| A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,131,677 | September 1, 2025 | August 31, 2027 | KOH, MEI YEE | reporter.nih.gov |
| Ketone Body Metabolism and Integrated Metabolic Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,128,893 | August 5, 2011 | June 30, 2025 | CRAWFORD, PETER A | reporter.nih.gov |
| Improving hepatocellular carcinoma mouse modeling by understanding the malignant potential and biology of liver cell subpopulations | NIH | National Cancer Institute | 2021 to 2024 | $2,123,250 | June 1, 2020 | May 31, 2025 | ZHU, HAO | reporter.nih.gov |
| A novel approach to treat non-alcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,122,291 | June 1, 2021 | July 31, 2024 | ARBEENY, CYNTHIA | reporter.nih.gov |
| Regulation of hepatic hepcidin expression by transferrin receptor-2 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,117,351 | August 15, 2021 | July 31, 2025 | ENNS, CAROLINE | reporter.nih.gov |
| Toxic lipid intermediate accumulation and cobalamin depletion promote AHR-mediated hepatotoxicity and the progression of non-alcoholic fatty liver disease (NAFLD)-like pathologies | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,117,038 | September 1, 2025 | August 31, 2027 | ZACHAREWSKI, TIMOTHY R. | reporter.nih.gov |
| Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,113,449 | September 15, 2023 | July 31, 2027 | KAPLAN, ROBERT C | reporter.nih.gov |
| Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,112,911 | September 25, 2011 | June 30, 2026 | SCHNABL, BERND G. | reporter.nih.gov |
| Pathophysiologic mechanisms leading to intrahepatic fat accumulation in obese youth | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $2,110,569 | April 21, 2021 | January 31, 2027 | SANTORO, NICOLA | reporter.nih.gov |
| Assessing performance of a Hepatitis C Emergency Department (HepC-END) Screening Tool | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,102,922 | September 15, 2023 | July 31, 2028 | PARK, HAESUK | reporter.nih.gov |
| Biological role and pharmacology of EXPERA family proteins and their effect onsterol homeostasis | NIH | National Institute of General Medical Sciences | 2025 | $2,102,917 | September 1, 2025 | August 31, 2029 | ALON, ASSAF | reporter.nih.gov |
| Thioesterase-mediated lipotoxicity in liver and thermogenic adipose tissue | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,101,800 | August 13, 2021 | April 30, 2027 | ERSOY, BARAN | reporter.nih.gov |
| A microsimulation of alcohol control interventions to advance health equity and reverse the current decrease in life expectancy in the US | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,099,693 | August 10, 2020 | July 31, 2026 | PROBST, CHARLOTTE | reporter.nih.gov |
| Mini-Livers Derived from Human IPS Cells for Modeling Steatosis and Therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,096,374 | August 1, 2014 | May 31, 2025 | SOTO-GUTIERREZ, ALEJANDRO | reporter.nih.gov |
| Protective and fibrosis-independent functions of hepatic stellate cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,093,748 | April 1, 2021 | March 31, 2026 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Mechanisms underlying hepatic immune cell recruitment in nonalcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,092,488 | April 1, 2021 | March 31, 2027 | RAEMAN, REBEN | reporter.nih.gov |
| TNF alpha and Recovery from Alcoholic Liver Injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,088,463 | May 5, 2025 | April 30, 2030 | DIEHL, ANNA MAE ELIZABETH | reporter.nih.gov |
| Xenobiotic-responsive hepatic long non-coding RNAs | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $2,078,339 | August 15, 2014 | April 30, 2026 | WAXMAN, DAVID J | reporter.nih.gov |
| Pathobiology of Liver Injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,077,361 | September 23, 2016 | August 31, 2026 | MALHI, HARMEET | reporter.nih.gov |
| Cholesterol toxicity in alcohol-associated hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $2,069,392 | May 15, 2023 | April 30, 2028 | JIANG, ZHENGHUI GORDON | reporter.nih.gov |
| Hepatic Steatosis Quantification with Ultrasound | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,068,831 | April 1, 2022 | March 31, 2027 | CHEN, SHIGAO | reporter.nih.gov |
| Role of alcohol adapted Kupffer cells in the progression and resolution of ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,068,172 | September 27, 2000 | February 29, 2028 | WEINMAN, STEVEN A | reporter.nih.gov |
| Synergistic effects of ECM and heterotypic crosstalk on cellular responses in non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,068,034 | February 8, 2018 | June 30, 2027 | KHETANI, SALMAN R | reporter.nih.gov |
| A novel cholinergic circuitry in alcoholic liver disease (NIAAA) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,066,485 | March 15, 2021 | January 31, 2027 | WU, JUN | reporter.nih.gov |
| A novel pathway controls liver injury in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,058,572 | June 23, 2022 | March 31, 2027 | ZHAO, PENG | reporter.nih.gov |
| Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,051,810 | September 1, 2023 | June 30, 2028 | SARKAR, MONIKA | reporter.nih.gov |
| Genetic Viral and Host Adaptations to Breach Species Barriers of HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,049,912 | July 1, 2013 | December 31, 2028 | PLOSS, ALEXANDER | reporter.nih.gov |
| LIFR-alpha/JAK/STAT3-dependent Adipose Inflammation Contributes to Obesity-Associated NAFLD - Resubmissi | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,048,146 | January 1, 2022 | December 31, 2026 | INFANTE, RODNEY E | reporter.nih.gov |
| Delineating the molecular mechanisms of hepatocyte-to-cholangiocyte reprogramming | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,044,853 | April 1, 2022 | March 31, 2026 | SHIN, DONGHUN | reporter.nih.gov |
| Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,039,441 | January 15, 2019 | December 31, 2025 | THOMAS, DAVID L | reporter.nih.gov |
| QSM to Guide Iron Chelating Therapy in Transfusional Iron Overload | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,037,010 | February 1, 2019 | January 31, 2025 | WANG, YI | reporter.nih.gov |
| Evaluating risk factors for cirrhosis progression and response to statin therapy among a cohort of patients with cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,035,766 | September 22, 2021 | July 31, 2027 | GOLDBERG, DAVID SETH | reporter.nih.gov |
| Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $2,035,065 | September 16, 2020 | August 31, 2025 | LERNER, DANIEL J | reporter.nih.gov |
| Factors Controlling Metabolic Flux in the Liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,034,463 | February 1, 2008 | February 28, 2027 | BURGESS, SHAWN C | reporter.nih.gov |
| Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,019,371 | December 1, 2021 | November 30, 2026 | GUO, SHAODONG | reporter.nih.gov |
| Development of caspase-6 inhibitors for treatment of NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,016,023 | January 1, 2023 | November 30, 2027 | SALTIEL, ALAN R. | reporter.nih.gov |
| Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $2,013,280 | September 20, 2021 | June 30, 2026 | TUCCI, FABIO COHEN | reporter.nih.gov |
| Microchip for HBV testing using HIV-infected blood samples | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,012,162 | February 6, 2023 | November 30, 2024 | SHAFIEE, HADI | reporter.nih.gov |
| Mechanisms of insulin resistance related to nonalcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,007,393 | March 9, 2015 | March 31, 2025 | CZECH, MICHAEL P | reporter.nih.gov |
| Parametric PET of Neuroinflammation for NAFLD-related AD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,006,919 | September 15, 2020 | August 31, 2024 | WANG, GUOBAO | reporter.nih.gov |
| Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,006,588 | July 1, 2022 | April 30, 2027 | WANG, SHUXIA | reporter.nih.gov |
| International Consortium for the Genetics of Biliary Tract Cancers Cholangiocarcinoma Genome Wide Association Study | NIH | National Cancer Institute | 2023 to 2025 | $2,005,621 | April 10, 2023 | March 31, 2028 | ROBERTS, LEWIS R | reporter.nih.gov |
| Imaging Hepatic Energy Metabolism in NAFLD/NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,004,135 | April 1, 2022 | December 31, 2026 | MERRITT, MATTHEW E | reporter.nih.gov |
| The role of liver progenitor cells in liver regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,003,650 | February 15, 2023 | January 31, 2027 | GOESSLING, WOLFRAM | reporter.nih.gov |
| Elucidating dietary fructose and alcohol interactions during liver cancer development | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,001,964 | August 1, 2021 | May 31, 2027 | JANG, CHOLSOON | reporter.nih.gov |
| Defining the Role of Intestinal Calcium Channels in Alcoholic Liver Damage. | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,001,739 | March 15, 2022 | February 28, 2027 | RAO, RADHAKRISHNA | reporter.nih.gov |
| Therapeutic antibodies for treating liver fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $1,999,998 | June 1, 2020 | July 31, 2025 | SCHWIMMER, LAUREN JENNIFER | reporter.nih.gov |
| Rapid point-of-care molecular test for HCV VL | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,996,224 | September 1, 2021 | March 31, 2027 | FISHER, JAY KENNETH | reporter.nih.gov |
| Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,986,219 | January 20, 2019 | December 31, 2025 | MCCLAIN, DONALD A. | reporter.nih.gov |
| Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,984,827 | September 14, 2023 | August 31, 2026 | TSENG, HSIAN-RONG | reporter.nih.gov |
| Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,984,107 | September 17, 2021 | July 31, 2025 | LERNER, DANIEL J | reporter.nih.gov |
| Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,982,398 | June 1, 2019 | May 31, 2024 | BURWITZ, BENJAMIN J | reporter.nih.gov |
| The characterization of Cela2a, a novel disease gene for metabolic syndrome in health and diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,979,595 | April 1, 2023 | March 31, 2028 | MANI, ARYA | reporter.nih.gov |
| A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,974,527 | March 1, 2021 | February 28, 2025 | RICE, CHARLES M | reporter.nih.gov |
| The Transitional Liver Clinic (TLC): Reducing Liver Disease Readmission | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,967,875 | February 1, 2023 | November 30, 2027 | ORMAN, ERIC | reporter.nih.gov |
| Tumor-promoting liver injuries and mechanisms | NIH | National Cancer Institute | 2021 to 2024 | $1,966,473 | February 20, 2020 | January 31, 2026 | FENG, GEN-SHENG | reporter.nih.gov |
| Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,966,264 | May 6, 2020 | April 30, 2026 | ROBEK, MICHAEL | reporter.nih.gov |
| Click Chemistry-Mediated Surface Protein Assay for Quantifying Subpopulations of Hepatocellular Carcinoma-associated Extracellular Vesicles | NIH | National Cancer Institute | 2023 to 2025 | $1,964,033 | July 1, 2023 | June 30, 2028 | ZHU, YAZHEN | reporter.nih.gov |
| Mass spectrometry for highly sensitive and sample-sparing analysis of extracellular vesicles in liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,963,066 | August 1, 2023 | May 31, 2027 | REVZIN, ALEXANDER | reporter.nih.gov |
| Hepatic stellate cells in NASH fibrosis and HCC | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,960,030 | April 1, 2021 | March 31, 2025 | FRIEDMAN, SCOTT L. | reporter.nih.gov |
| A Precision Medicine for Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $1,959,401 | September 20, 2023 | August 31, 2025 | LIU, WANQING | reporter.nih.gov |
| Interferon regulation by NBR1-driven chaperone-mediated autophagy in stellate cells in liver cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,950,900 | December 1, 2021 | November 30, 2026 | MOSCAT, JORGE | reporter.nih.gov |
| San Diego Cirrhosis Clinical Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,949,305 | September 9, 2021 | July 31, 2027 | LOOMBA, ROHIT | reporter.nih.gov |
| Molecular Mechanisms of HBV cccDNA Formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,933,309 | March 11, 2016 | June 30, 2027 | GUO, HAITAO | reporter.nih.gov |
| Developing a renewable and dissectible human liver for the study of HBV/HCV infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,932,000 | August 18, 2022 | July 31, 2027 | WU, XIANFANG | reporter.nih.gov |
| Point of Care Diagnostics for Liver Disease using Fluorescent Nanosensors | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,929,527 | February 1, 2020 | July 31, 2028 | ROTELLO, VINCENT M. | reporter.nih.gov |
| LXR-Dependent Cholesterol Sensing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,928,942 | April 1, 2022 | June 30, 2026 | SCHULMAN, IRA G | reporter.nih.gov |
| Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach | NIH | National Cancer Institute | 2021 to 2025 | $1,928,339 | May 1, 2012 | June 30, 2027 | LUBMAN, DAVID M. | reporter.nih.gov |
| Maternal effect on offspring immunity against hepatitis B virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,925,049 | July 3, 2019 | June 30, 2025 | OU, J.-H. JAMES | reporter.nih.gov |
| The role of hepatocyte necroptosis and inflammation in liver-brain crosstalk in aging | NIH | National Institute on Aging | 2021 to 2025 | $1,923,555 | May 1, 2019 | June 30, 2029 | SATHYASEELAN, DEEPA | reporter.nih.gov |
| Sphingosine kinase 2 in sexual dimorphism of hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,923,553 | September 1, 2022 | August 31, 2027 | GREEN, CHRISTOPHER D | reporter.nih.gov |
| Copper and copper-binding proteins in insulin resistance-associated metabolic disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,917,728 | August 8, 2022 | June 30, 2026 | MIAO, JI | reporter.nih.gov |
| Dissecting the NRG4 hormonal checkpoint in metabolic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,912,088 | July 15, 2015 | June 30, 2025 | LIN, JIANDIE D | reporter.nih.gov |
| Environmental Liver Disease | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,909,704 | September 15, 2017 | August 31, 2025 | CAVE, MATTHEW C | reporter.nih.gov |
| Molecular Mechanisms of Liver Fibrosis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,908,852 | May 1, 2022 | April 30, 2027 | SHAH, VIJAY H. | reporter.nih.gov |
| Molecular Mechanisms of TRIB1 Regulation of Hepatic Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,907,161 | May 1, 2023 | April 30, 2027 | BAUER, ROBERT CLAYTON | reporter.nih.gov |
| Contributions of Hepatic and Intestinal Pathways to Cholesterol Excretion | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,904,680 | September 13, 2017 | March 31, 2027 | GRAF, GREGORY A | reporter.nih.gov |
| Targeting SGLTs for liver disease in a rabbit model of cystic fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,904,215 | July 1, 2023 | April 30, 2027 | XU, JIE | reporter.nih.gov |
| Modulation of the liver-brain axis by alcohol and its impact on Alzheimers disease pathology | NIH | National Institute on Aging | 2021 to 2024 | $1,899,958 | September 30, 2020 | June 30, 2026 | HAN, DERICK S | reporter.nih.gov |
| Severe neonatal hyperbilirubinemia (SNH) and the expression of UDP-glucuronosyltransferase 1A1 (UGT1A1) play key roles in the development of necrotizing enterocolitis (NEC) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,894,402 | July 1, 2023 | April 30, 2028 | TUKEY, ROBERT H | reporter.nih.gov |
| Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,893,133 | February 3, 2021 | January 31, 2026 | MICHALOPOULOS, GEORGE K | reporter.nih.gov |
| UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,891,335 | July 14, 2020 | March 31, 2024 | WISEMAN, ROCKLAND LUKE | reporter.nih.gov |
| Liver Pathobiology: insights through the lens of rare diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,890,194 | July 1, 2022 | April 30, 2027 | VILARINHO, SILVIA | reporter.nih.gov |
| BCM/TCH Cholestatic Liver Disease Consortium | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,886,576 | September 10, 2014 | May 31, 2029 | SHNEIDER, BENJAMIN L | reporter.nih.gov |
| Role of adipose mRNA modifications in metabolic disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,877,990 | March 1, 2022 | February 28, 2027 | RUI, LIANGYOU | reporter.nih.gov |
| Role of HCV exosomes in intercellular communication | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,877,240 | April 15, 2020 | February 28, 2026 | HAHN, YOUNG S. | reporter.nih.gov |
| A new mechanism of hepatocyte proliferation under stress | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,872,196 | March 1, 2021 | February 28, 2026 | FENG, GEN-SHENG | reporter.nih.gov |
| Social determinants of fatty liver disease and its racial/ethnic disparities: The Multi-Ethnic Study of Atherosclerosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,869,561 | July 15, 2023 | May 31, 2027 | LAZO ELIZONDO, MARIANA | reporter.nih.gov |
| Testing an mHealth System for Integrating Alcohol Use Treatment with Hepatology Care for Patients with Alcohol-associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,867,751 | September 20, 2023 | August 31, 2028 | QUANBECK, ANDREW | reporter.nih.gov |
| Modeling Viral and T Lymphocyte Dynamics | NIH | Office of the Director, National Institutes of Health | 2021 to 2024 | $1,866,528 | December 23, 2019 | November 30, 2025 | PERELSON, ALAN S | reporter.nih.gov |
| Dissecting the Acid Ceramidase Pathway in Hepatic Fibrogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,865,204 | August 15, 2023 | May 31, 2028 | CHEN, JENNIFER Y. | reporter.nih.gov |
| Hepatic Stellate Cell Regulation of Metastatic Growth in the Liver | NIH | National Cancer Institute | 2021 to 2025 | $1,859,744 | September 1, 2011 | July 31, 2027 | KANG, NINGLING | reporter.nih.gov |
| Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,857,031 | September 1, 2019 | August 31, 2025 | VINIKOOR, MICHAEL JEFFREY | reporter.nih.gov |
| Hepatic steatosis promotes liver metastasis | NIH | National Cancer Institute | 2022 to 2025 | $1,857,013 | January 1, 2022 | November 30, 2026 | ROHATGI, NIDHI | reporter.nih.gov |
| Biomarkers to Identify Individuals at RIsk for Progression of S. Japonicum Associated Hepatic Fibrosis with Point of Care Test Development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,852,531 | June 1, 2022 | March 31, 2027 | FRIEDMAN, JENNIFER F | reporter.nih.gov |
| Vinyl chloride modifies the risk for nonalcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,847,149 | July 1, 2022 | April 30, 2027 | BEIER, JULIANE I | reporter.nih.gov |
| Pre-clinical Validation of A Novel Protein Drug Candidate for ASH and NASH Treatment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,843,194 | September 1, 2021 | June 30, 2025 | YANG, JENNY J. | reporter.nih.gov |
| The Regulation of Hepatic Metabolic Zonation by the Diabetes Gene TCF7L2 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,840,600 | January 1, 2022 | December 31, 2026 | NORTON, LUKE | reporter.nih.gov |
| Therapeutic Potential of Estrogen-Regulated Metabolism and Cardiovascular Risk | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,835,045 | March 1, 2016 | April 30, 2025 | STAFFORD, JOHN MICHAEL | reporter.nih.gov |
| Goblet cells and intestinal immune response in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,834,660 | August 10, 2022 | April 30, 2027 | LLORENTE IZQUIERDO, ANA CRISTINA | reporter.nih.gov |
| Michigan Hepatotoxicity Clinical Research Network Renewal | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,834,456 | September 30, 2003 | July 31, 2028 | FONTANA, ROBERT J | reporter.nih.gov |
| Smart-phone-integrated, non-invasive, depth-resolved optical spectroscopy for the detection of neonatal jaundice | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,826,760 | August 8, 2022 | April 30, 2027 | BOWDEN, AUDREY KYNSELLA | reporter.nih.gov |
| Dissecting AAV silencing in humanized mice | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,823,990 | February 1, 2023 | January 31, 2027 | BISSIG, KARL-DIMITER | reporter.nih.gov |
| Novel pathways in the pathogenesis and pathophysiology of NAFLD in Hispanics | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $1,820,623 | March 12, 2019 | November 30, 2024 | NAJJAR, SONIA M. | reporter.nih.gov |
| The Role of Macrophages in Hepatobiliary Development | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,815,657 | May 1, 2023 | March 31, 2028 | GOESSLING, WOLFRAM | reporter.nih.gov |
| Interaction between Genome and Heavy Metals in Nonalcoholic Fatty Liver Disease | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $1,814,912 | June 15, 2023 | March 31, 2028 | LIU, WANQING | reporter.nih.gov |
| Pathogenic Role of Foxl1+ Hepatic Progenitor Cells in Fibrotic Liver Disease | NIH | National Cancer Institute | 2021 to 2025 | $1,813,542 | December 1, 2023 | November 30, 2026 | SHIN, SOONA | reporter.nih.gov |
| Molecular and cellular basis of the renal diseases associated with Alagille Syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,811,392 | May 1, 2021 | February 28, 2027 | SURENDRAN, KAMESWARAN | reporter.nih.gov |
| IRAKM and MINCLE in ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,806,489 | August 17, 2023 | July 31, 2028 | NAGY, LAURA E. | reporter.nih.gov |
| Rapid, Point-of-Care Diagnostics for Hepatitis C Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,799,981 | August 12, 2022 | August 12, 2025 | UNGEWITTER, ERICA | reporter.nih.gov |
| The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,799,014 | May 1, 2022 | March 31, 2027 | DONG, X. CHARLIE | reporter.nih.gov |
| USC Cirrhosis Clinical Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,796,054 | September 22, 2021 | July 31, 2027 | TERRAULT, NORAH A. | reporter.nih.gov |
| Resolving Uncertainty in Alagille Syndrome Diagnostics | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,789,630 | July 1, 2023 | April 30, 2028 | SPINNER, NANCY BETTINA | reporter.nih.gov |
| Injury, Progression, and Fibrosis of the Extrahepatic Bile Duct | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,789,450 | August 1, 2019 | April 30, 2027 | WELLS, REBECCA G | reporter.nih.gov |
| Role of Retinoid X Receptor Alpha in regulating PCSK9 transcription in the liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,789,027 | April 1, 2023 | January 31, 2027 | MIAO, QING | reporter.nih.gov |
| Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,786,691 | May 1, 2023 | April 30, 2026 | PARHAMI, FARHAD | reporter.nih.gov |
| Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,783,750 | April 1, 2020 | March 31, 2026 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| In search of an HBV cure: novel model systems and targets | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,782,852 | June 10, 2019 | May 31, 2024 | RICE, CHARLES M | reporter.nih.gov |
| AlcHepNet DCC UMMS | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,781,820 | August 1, 2018 | June 30, 2024 | BARTON, BRUCE A | reporter.nih.gov |
| Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,775,918 | September 20, 2021 | July 31, 2027 | MOYLAN, CYNTHIA A | reporter.nih.gov |
| Molecular Mechanisms of Cholestatic Fibrogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,775,340 | February 15, 2019 | January 31, 2028 | HUEBERT, ROBERT CHRISTIAN | reporter.nih.gov |
| Comprehensive noninvasive assessment of liver histopathology in nonalcoholic fatty liver disease (NAFLD) via magnetic resonance imaging, cytometry and elastography (MR-ICE) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $1,774,440 | May 1, 2014 | November 30, 2026 | YIN, MENG | reporter.nih.gov |
| PPARa and related nuclear receptors in non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,772,925 | April 1, 2021 | March 31, 2026 | LAZAR, MITCHELL A. | reporter.nih.gov |
| Continuation of the Childhood Liver Disease Research Network - Seattle Clinical Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,770,356 | September 10, 2009 | May 31, 2029 | VALENTINO, PAMELA | reporter.nih.gov |
| Transcriptional and non-transcriptional function of IRF3 in ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,763,975 | July 5, 2019 | June 30, 2029 | NAGY, LAURA E. | reporter.nih.gov |
| Lipotoxicity and Maintenance of Metabolic Health | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,762,959 | July 1, 2023 | April 30, 2027 | SCHAFFER, JEAN E. | reporter.nih.gov |
| Mediators of fatty liver disease during HIV/SIV and cART treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,758,840 | February 19, 2018 | January 31, 2024 | SODORA, DONALD L | reporter.nih.gov |
| Methionine Adenosyltransferase α1 and Its Interactome in Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,756,216 | May 15, 2018 | March 31, 2029 | LU, SHELLY CHI-LOO | reporter.nih.gov |
| Yittrium-90 radiation lobectomy: Dose optimization and prediction of FLR hypertrophy to enable resection of HCC | NIH | National Cancer Institute | 2022 to 2025 | $1,755,197 | August 1, 2019 | July 31, 2026 | LEWANDOWSKI, ROBERT J | reporter.nih.gov |
| Hepatic stellate cell plasticity and maladaptive fibrogenic memory in chronic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,752,856 | April 1, 2023 | February 29, 2028 | WANG, SHUANG | reporter.nih.gov |
| Notch, Type 2 Diabetes and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,752,429 | July 1, 2015 | March 31, 2024 | PAJVANI, UTPAL | reporter.nih.gov |
| Role of phospho UBC9 in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,749,454 | September 10, 2022 | July 31, 2027 | TOMASI, MARIA LAUDA | reporter.nih.gov |
| Metabolic Reprogramming by Protease-activated Receptor 2 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $1,746,288 | February 15, 2022 | November 30, 2025 | KULIOPULOS, ATHAN | reporter.nih.gov |
| Amino Acids and Pediatric Hepatic Steatosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,743,505 | September 20, 2023 | August 31, 2025 | WOLFE, ROBERT R | reporter.nih.gov |
| Pathophysiology of Biliary Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,742,958 | April 1, 2001 | June 30, 2027 | LARUSSO, NICHOLAS F. | reporter.nih.gov |
| Mechanisms regulating autophagy in alcohol-induced liver injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,738,874 | May 1, 2022 | April 30, 2027 | DING, WEN-XING | reporter.nih.gov |
| Nuclear Repressors in Genomic Control of Healthful Obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,735,319 | May 10, 2016 | July 31, 2025 | BARISH, GRANT D | reporter.nih.gov |
| Pathobiology of Nonalcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,735,008 | September 30, 2021 | July 31, 2026 | HIRSOVA, PETRA | reporter.nih.gov |
| 1/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,732,406 | August 1, 2023 | July 31, 2030 | TERRAULT, NORAH A. | reporter.nih.gov |
| Immunopathogenesis of non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,731,144 | September 5, 2013 | July 31, 2025 | DIVANOVIC, SENAD | reporter.nih.gov |
| Novel Liver Signaling Pathways Controlling Adiposity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,727,102 | July 3, 2020 | December 31, 2024 | HINDS, TERRY D | reporter.nih.gov |
| Copper Homeostasis and Liver Function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,710,921 | May 1, 2018 | December 31, 2027 | LUTSENKO, SVETLANA | reporter.nih.gov |
| Mannose metabolism as a regulator of hepatic stellate cell activation and fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,709,114 | January 1, 2020 | December 31, 2025 | CHU, JAIME C | reporter.nih.gov |
| Integrated therapies for alcohol use and ALD (ITAALD) Network - IU Clinical Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,707,981 | September 15, 2012 | June 30, 2029 | CHALASANI, NAGA P | reporter.nih.gov |
| A new humanized mouse model to study HBV gene editing | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,705,880 | August 1, 2024 | July 31, 2029 | JEROME, KEITH R | reporter.nih.gov |
| Role of the Macrophage in Developmentally Programmed NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,703,451 | July 1, 2020 | June 30, 2025 | FRIEDMAN, JACOB E | reporter.nih.gov |
| PPARgamma-regulated mechanisms in hepatocytes that promote NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,702,743 | February 1, 2022 | January 31, 2027 | CORDOBA-CHACON, JOSE | reporter.nih.gov |
| Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $1,697,097 | March 1, 2021 | February 28, 2025 | YANG, KYUNGHEE | reporter.nih.gov |
| Role of alcohol-induced ghrelin in modulating organ crosstalk to promote the development of fatty liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,696,075 | June 15, 2021 | May 31, 2027 | RASINENI, KARUNA | reporter.nih.gov |
| Hepatic TrkB-T1 signaling in NASH pathogenesis and resolution | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,695,001 | April 1, 2023 | January 31, 2027 | LIN, JIANDIE D | reporter.nih.gov |
| Hepatic mTORC1 Signaling and the Regulation of Lipid Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,694,012 | March 1, 2021 | January 31, 2025 | TITCHENELL, PAUL MICHAEL | reporter.nih.gov |
| A Precision Targeted Therapeutics for Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,693,379 | July 1, 2021 | April 30, 2026 | LIU, WANQING | reporter.nih.gov |
| Quantifying Body Composition and Liver Disease in Children using Free-Breathing MRI and MRE | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,692,766 | May 8, 2020 | February 28, 2026 | WU, HOLDEN H | reporter.nih.gov |
| Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,689,302 | May 8, 2020 | February 28, 2026 | CUSI, KENNETH | reporter.nih.gov |
| Matrix in pre-cirrhotic HCC | NIH | National Cancer Institute | 2023 to 2025 | $1,687,806 | March 15, 2023 | February 29, 2028 | TOROK, NATALIE J. | reporter.nih.gov |
| Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,686,928 | August 15, 2020 | April 30, 2024 | DAHL, JEREMY | reporter.nih.gov |
| FGFR Signaling in Liver Injury and Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,679,893 | July 1, 2022 | April 30, 2027 | MAVILA, NIRMALA | reporter.nih.gov |
| Role of Soluble Epoxide Hydrolase in Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,662,196 | June 1, 2022 | March 31, 2027 | KIRPICH, IRINA A. | reporter.nih.gov |
| Role of SAMe in the Progression of Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,656,555 | September 20, 2002 | June 30, 2026 | LU, SHELLY CHI-LOO | reporter.nih.gov |
| Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $1,655,480 | February 1, 2022 | January 31, 2026 | PRENDERGAST, GEORGE C | reporter.nih.gov |
| Non-Invasive Imaging of Neurological Glycogen Storage Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,648,635 | April 1, 2022 | March 31, 2027 | YADAV, NIRBHAY NARAYAN | reporter.nih.gov |
| Therapeutic roles of hepatocyte exosomes in the liver | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $1,646,470 | March 1, 2020 | February 28, 2026 | BRIGSTOCK, DAVID R | reporter.nih.gov |
| Lipotoxicity in Alcoholic Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $1,644,580 | September 30, 2009 | June 30, 2025 | ZHOU, ZHANXIANG | reporter.nih.gov |
| Chemoproteomic Identification and Therapeutic Validation of Proteins of Metabolic Significance | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $1,640,587 | August 1, 2017 | July 31, 2023 | SAEZ, ENRIQUE | reporter.nih.gov |
| Role of Beta Spectrin and Smad in Alcohol-Induced Liver and GI Cell Proliferation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,640,516 | August 20, 2024 | July 31, 2029 | MISHRA, LOPA | reporter.nih.gov |
| Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors | NIH | National Cancer Institute | 2021 to 2023 | $1,637,378 | December 1, 2018 | November 30, 2024 | KARIN, MICHAEL | reporter.nih.gov |
| Sulfur Amino Acid Metabolism and Regulation of Hepatic Metabolic Flexibility | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,632,006 | January 1, 2022 | December 31, 2025 | LI, TIANGANG | reporter.nih.gov |
| Disturbed Crosstalk between Cholesterol Homeostasis and Inflammation Resolution in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,626,085 | May 1, 2023 | August 10, 2025 | CAI, BISHUANG | reporter.nih.gov |
| Lipidated Amino Acids in Cardiometabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,621,509 | June 2, 2022 | March 31, 2027 | ROM, OREN | reporter.nih.gov |
| Developing Woodchucks Susceptible to Hepatitis B Virus Infection by Modifying the Virus or Host | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,621,356 | July 17, 2024 | June 30, 2029 | MENNE, STEPHAN | reporter.nih.gov |
| Coordination of hepatic fatty acid metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,621,125 | September 15, 2020 | May 31, 2025 | WOLFGANG, MICHAEL J. | reporter.nih.gov |
| Glycopathology of HCC: identification of the source cells of serum fucosylation | NIH | National Cancer Institute | 2021 to 2023 | $1,620,312 | March 14, 2019 | February 28, 2025 | MEHTA, ANAND S. | reporter.nih.gov |
| Liver Cirrhosis Network: Clinical Research Centers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,615,873 | September 13, 2021 | July 31, 2027 | SANYAL, ARUN J | reporter.nih.gov |
| Novel coagulation-dependent mechanisms of liver regeneration to detect and prevent liver dysfunction after partial hepatectomy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,615,336 | July 1, 2020 | June 30, 2026 | LUYENDYK, JAMES P | reporter.nih.gov |
| Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,615,258 | May 15, 2018 | April 30, 2025 | STANLEY, TAKARA LEAH | reporter.nih.gov |
| Alcohol-induced hepatotoxicity - implications of secretin/secretin receptor axis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,614,707 | September 5, 2020 | September 11, 2023 | ALPINI, GIANFRANCO D | reporter.nih.gov |
| Role of Peritoneal Macrophage in Spontaneous Bacterial Peritonitis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,612,305 | July 1, 2023 | June 30, 2028 | SAITO, TAKESHI | reporter.nih.gov |
| A multi-modular approach for human pluripotent stem cell-based liver regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,608,063 | September 15, 2020 | July 31, 2025 | GOUON-EVANS, VALERIE B | reporter.nih.gov |
| Tissue-Specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $1,608,004 | September 1, 2018 | June 30, 2025 | SCHWARZ, JEAN-MARC | reporter.nih.gov |
| Hepatic Nicotinamide N-Methyltransferase (NNMT) as a Pathogenetic Mechanism and Therapeutic Target for Alcoholic Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,597,329 | August 15, 2022 | May 31, 2027 | SONG, ZHENYUAN | reporter.nih.gov |
| Coactivator P300 promotes hepatic steatosis in obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,595,209 | April 1, 2019 | March 31, 2025 | HE, LING | reporter.nih.gov |
| Inhibition of hepatic (V)LDL production by a novel antagonist of carboxyl esterase 1 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,594,367 | September 1, 2023 | August 31, 2027 | DUNCAN, STEPHEN A | reporter.nih.gov |
| Hepatic insulin resistance integrates T2D and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,593,841 | September 5, 2024 | July 31, 2028 | WHITE, MORRIS F. | reporter.nih.gov |
| Inflammation and hepatic lipid metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,576,278 | July 1, 2020 | June 30, 2025 | SALTIEL, ALAN R. | reporter.nih.gov |
| Animal Model to study heterogeneous outcomes of HCV Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,575,922 | June 1, 2024 | April 30, 2029 | KAPOOR, AMIT | reporter.nih.gov |
| Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,574,788 | March 15, 2019 | February 28, 2025 | SHULMAN, GERALD I | reporter.nih.gov |
| Altering Hepatitis B Virus assembly through pharmacological intervention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,572,240 | May 6, 2020 | April 30, 2026 | GUMBART, JAMES C. | reporter.nih.gov |
| Sphingolipids in alcoholic liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,569,186 | July 1, 2023 | April 30, 2028 | ZHOU, HUIPING | reporter.nih.gov |
| Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse model | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,568,998 | June 12, 2024 | May 31, 2029 | RICE, CHARLES M | reporter.nih.gov |
| Bile acids and metabolic surgery | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,568,160 | September 14, 2020 | May 31, 2026 | HUANG, WENDONG | reporter.nih.gov |
| Dissecting Hepatitis B Vaccine Adjuvant Effects on Immune Responses and the HIV Reservoir in PLWH | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,567,217 | July 25, 2024 | May 31, 2029 | COX, ANDREA L | reporter.nih.gov |
| Novel Mechanisms of Hepatopulmonary Syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,567,158 | June 1, 2018 | April 30, 2025 | KAWUT, STEVEN M | reporter.nih.gov |
| Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,566,354 | September 24, 2018 | August 31, 2024 | SU, LISHAN | reporter.nih.gov |
| Long-acting Antiviral Treatment for HBV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,562,010 | July 10, 2024 | June 30, 2029 | HO, RODNEY J.Y. | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,561,055 | August 1, 2018 | June 30, 2029 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,560,000 | September 22, 2020 | August 31, 2025 | KUPIEC-WEGLINSKI, JERZY W | reporter.nih.gov |
| Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,559,904 | August 15, 2022 | May 31, 2027 | FENG, WENKE | reporter.nih.gov |
| Extracellular vesicles as the vehicles for promoting liver injury induced by HIV and alcohol | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,555,306 | February 10, 2019 | January 31, 2025 | OSNA, NATALIA ALEKSANDR | reporter.nih.gov |
| Novel therapeutic approach for NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,553,952 | June 4, 2020 | May 31, 2025 | MAITRA, RANGAN | reporter.nih.gov |
| Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,553,826 | December 1, 2017 | November 30, 2024 | LO RE, VINCENT | reporter.nih.gov |
| Genetic regulation of ductular reaction in liver injury and regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,552,488 | April 1, 2022 | January 31, 2026 | SRINIVASAN, SHANTHI K | reporter.nih.gov |
| Epigenetic Regulation of HBV cccDNA Transcription | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,551,736 | June 16, 2020 | May 31, 2026 | GUO, HAITAO | reporter.nih.gov |
| Impact of GLP-1 on Hepatic Fat and Energy Utilization in Obese Girls with Polycystic Ovarian Syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,550,613 | August 1, 2019 | July 31, 2025 | CREE, MELANIE G | reporter.nih.gov |
| ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,549,999 | April 3, 2023 | August 25, 2025 | ZHANG, YANG-YUAN | reporter.nih.gov |
| HBV cccDNA transcriptional silencing with and without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,548,735 | July 22, 2024 | May 31, 2029 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Linking fat metabolism to hepatic fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,547,010 | April 1, 2020 | March 31, 2024 | NAJJAR, SONIA M. | reporter.nih.gov |
| NASH-associated macrophages: regulation and role in disease pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,545,379 | April 1, 2023 | January 31, 2027 | LIN, JIANDIE D | reporter.nih.gov |
| Protective role of OPN-High macrophages in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,545,316 | August 5, 2023 | May 31, 2027 | NIETO, NATALIA | reporter.nih.gov |
| Determining hepatocyte-specific mechanisms by which Ube4A regulates NAFLD/NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,543,965 | March 15, 2023 | March 9, 2025 | CHAKRABORTY, ANUTOSH | reporter.nih.gov |
| Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,541,402 | April 1, 2023 | January 31, 2028 | SHU, YAN | reporter.nih.gov |
| Glycerol Regulation of Gluconeogenesis and Fatty Acid Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,539,254 | August 7, 2023 | May 31, 2027 | WONDISFORD, FREDRIC E. | reporter.nih.gov |
| Roles of peroxisomal dysfunction in alcohol-related liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,538,891 | June 1, 2023 | February 29, 2028 | ZHONG, WEI | reporter.nih.gov |
| Influence of integrant-derived HBV RNAs encoding the envelope proteins on HBV life cycle | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,537,333 | February 4, 2022 | January 31, 2027 | GUDIMA, SEVERIN O | reporter.nih.gov |
| Early Life Exposure to Endocrine Disrupting Chemicals: Epigenomic and Transcriptomic Networks and RAGE in Liver Disease | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,535,323 | April 17, 2024 | March 31, 2027 | TREVINO, LINDSEY STARR | reporter.nih.gov |
| Mechanisms and therapeutic potential of blocking the mitochondrial Mg2+ channel Mrs2 in obesity and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,534,364 | April 1, 2023 | January 31, 2027 | MUNISWAMY, MADESH | reporter.nih.gov |
| Reducing Vertical Transmission of Hepatitis B in Africa (REVERT-B Trial) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,534,174 | May 18, 2020 | March 31, 2026 | DIONNE, JODIE ANN | reporter.nih.gov |
| Genetic basis of virus induced Biliary Atresia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,533,843 | April 1, 2011 | January 31, 2029 | TIAO, GREGORY M | reporter.nih.gov |
| Avoiding Cardiovascular Complications in Liver Transplantation through Novel Studies (ACCT NOW) in Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,533,772 | August 15, 2024 | May 31, 2027 | VANWAGNER, LISA B | reporter.nih.gov |
| Engaging People Who Use Drugs in Harm Reduction Service Delivery: An Intravention to Reduce Risk of HIV, HCV, Overdose, and Injection-related Infections in Rural Appalachia | NIH | National Institute on Drug Abuse | 2024 | $1,533,697 | September 30, 2024 | August 31, 2026 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Mapping, programming, and correcting gene regulatory sequences for Alagille Syndrome | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,533,046 | December 15, 2023 | November 30, 2027 | ENGREITZ, JESSE M | reporter.nih.gov |
| An NADH-ChREBP axis in fatty liver disease and dyslipidemia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,532,519 | February 15, 2023 | November 30, 2027 | GOODMAN, RUSSELL PAUL | reporter.nih.gov |
| Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,528,985 | July 3, 2024 | May 31, 2029 | POSNER, JONATHAN D | reporter.nih.gov |
| O-glycoproteins in the progression of liver disease | NIH | National Cancer Institute | 2021 to 2023 | $1,525,161 | July 1, 2019 | June 30, 2024 | GOLDMAN, RADOSLAV | reporter.nih.gov |
| Elucidating the role of the FXR-PTEN-PI3K-AKT-mTOR axis in liver progenitor cell-driven liver regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,523,928 | September 25, 2014 | May 31, 2025 | SHIN, DONGHUN | reporter.nih.gov |
| Cross talk between epithelial, inflammatory and mesenchymal cells in the development of portal fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,522,465 | May 1, 2015 | August 31, 2024 | STRAZZABOSCO, MARIO | reporter.nih.gov |
| Role of the Cell Adhesome in Obesity-related Liver Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,519,014 | July 1, 1995 | June 30, 2025 | MCGUINNESS, OWEN P | reporter.nih.gov |
| Cellular interactions between TGF-beta pathway members and epigenetic regulators in liver and gastrointestinal cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,518,039 | July 18, 2018 | March 31, 2029 | MISHRA, LOPA | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Virginia Commonwealth University | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,515,775 | August 1, 2018 | June 30, 2029 | ARAB, JUAN PABLO | reporter.nih.gov |
| The Role of ERRa in liver lipid dysfunction and pathology | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,515,199 | December 1, 2021 | November 30, 2026 | STILES, BANGYAN | reporter.nih.gov |
| A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,512,500 | September 25, 2020 | June 3, 2024 | TIBBITTS, JAY | reporter.nih.gov |
| Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,510,271 | September 13, 2021 | July 31, 2027 | SHAH, VIJAY H. | reporter.nih.gov |
| Elucidating chronic liver disease pathways using somatic genetics | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,508,800 | September 15, 2024 | June 30, 2029 | ZHU, HAO | reporter.nih.gov |
| Redox Regulation of O-GlcNAcylation Signaling in the Pathogenesis of Alcoholic Fatty Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,507,500 | May 1, 2022 | February 28, 2027 | CHEN, YING | reporter.nih.gov |
| Alcohol and Monocyte Signaling Administrative Supplement | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $1,506,751 | April 1, 1998 | March 31, 2029 | SZABO, GYONGYI | reporter.nih.gov |
| The Pittsburgh Cholestatic Liver Disease Consortium | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,500,894 | September 15, 2002 | May 31, 2026 | HORSLEN, SIMON | reporter.nih.gov |
| Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,498,133 | April 1, 2019 | March 31, 2025 | GOLDBERG, DAVID SETH | reporter.nih.gov |
| Role of cholinergic innervation of the liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,495,556 | December 23, 2022 | November 30, 2026 | JO, YOUNG-HWAN | reporter.nih.gov |
| The role of matrix-bound microvesicles in alcohol-related liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,492,976 | May 15, 2023 | March 31, 2028 | SCOTT, MELANIE J. | reporter.nih.gov |
| Mitochondrial NAD kinase: function and mechanism in metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,492,956 | April 1, 2022 | March 31, 2027 | ZHANG, REN | reporter.nih.gov |
| Integrative Role of Bilirubin on Obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,491,651 | April 1, 2020 | January 31, 2025 | STEC, DAVID E | reporter.nih.gov |
| Development of a hamster model for hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,485,242 | August 9, 2024 | July 31, 2029 | WANG, ZHONGDE | reporter.nih.gov |
| Hepatitis B virus e antigen in viral persistence | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,485,000 | February 20, 2017 | January 31, 2028 | OU, J.-H. JAMES | reporter.nih.gov |
| Growth Hormone Regulation of Sex Differences in Liver Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,484,972 | September 16, 2019 | May 31, 2025 | WAXMAN, DAVID J | reporter.nih.gov |
| Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,479,996 | July 1, 2023 | April 30, 2028 | COHEN, DAVID E. | reporter.nih.gov |
| Coordinate Regulation of an Alcohol Protective Response by the Liver-derived Hormone FGF21 | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $1,475,906 | August 10, 2020 | July 31, 2025 | KLIEWER, STEVEN A. | reporter.nih.gov |
| Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,469,096 | August 1, 2018 | June 30, 2029 | MITCHELL, MACK CLARENCE | reporter.nih.gov |
| Phospholipid-Mediated Metabolic Control in the Pathogenesis of NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $1,464,880 | December 23, 2021 | March 31, 2026 | COHEN, DAVID E. | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) – Mayo Clinic | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,459,312 | August 1, 2018 | June 30, 2029 | SHAH, VIJAY H. | reporter.nih.gov |
| Translation of a biomarker panel for the early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $1,458,768 | September 18, 2019 | August 31, 2024 | MEHTA, ANAND S. | reporter.nih.gov |
| Postprandial Vitamin A | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,457,662 | August 1, 2004 | May 31, 2025 | BLANER, WILLIAM S | reporter.nih.gov |
| Mechanisms linking the Branched-Chain alpha-Keto Acid regulatory network to the pathogenesis of NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,457,604 | April 15, 2023 | January 31, 2028 | WHITE, PHILLIP J | reporter.nih.gov |
| Identification of the Exposome in Fatty Liver Disease in Mexican American Families Using Genetic Correction | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,454,720 | April 27, 2018 | November 30, 2024 | BLANGERO, JOHN | reporter.nih.gov |
| Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $1,450,638 | September 25, 2018 | August 31, 2024 | KARIN, MICHAEL | reporter.nih.gov |
| Clinical Research Network in Nonalcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,447,477 | July 1, 2002 | June 30, 2027 | KOWDLEY, KRIS | reporter.nih.gov |
| Renal Disposition in NASH | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,446,306 | February 1, 2019 | January 31, 2025 | CHERRINGTON, NATHAN J | reporter.nih.gov |
| Regulation of Bile Acid Metabolism and Signaling in Metabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,445,336 | February 5, 2019 | April 30, 2030 | LI, TIANGANG | reporter.nih.gov |
| The Role of Tcf7l2 in maintaining liver zonation and metabolic homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,443,878 | February 1, 2023 | January 31, 2028 | BIDDINGER, SUDHA B | reporter.nih.gov |
| Pharmacologic targeting of the UPR in obesity-linked liver dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,443,302 | January 15, 2024 | November 30, 2027 | SAEZ, ENRIQUE | reporter.nih.gov |
| Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost Extension | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,441,353 | August 15, 2017 | July 31, 2023 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| Universal HCV screening in pregnancy: Examining testing uptake and HCV care | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,439,607 | September 30, 2024 | July 31, 2029 | KAPADIA, SHASHI | reporter.nih.gov |
| Lipid-Mediated Control of Acetyl-CoA Metabolism in the Pathogenesis of NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,439,582 | February 1, 1996 | December 31, 2027 | COHEN, DAVID E. | reporter.nih.gov |
| Characterizing zonated hepatocyte sexual dimorphism and its role in fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,437,820 | February 1, 2023 | January 31, 2028 | WANG, BRUCE MAO ZHENG | reporter.nih.gov |
| Noninvasive Monitoring of Hepatic Glutathione Depletion Through Blood Test | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,437,167 | April 1, 2021 | January 31, 2026 | ZHENG, JIE | reporter.nih.gov |
| Circadian and mitochondrial dysfunction in alcohol-related liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,434,258 | May 10, 2023 | March 31, 2028 | BAILEY, SHANNON MARIE | reporter.nih.gov |
| The Imprinted Gene Network in the programming of Non-Alcoholic Fatty Liver Disease by early life cadmium exposure | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,433,469 | May 19, 2020 | March 31, 2026 | COWLEY, MICHAEL | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Johns Hopkins University | Baltimore, MD | 34 | $67.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 52 | $60.5 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 40 | $59.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 44 | $58 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 36 | $52.3 million | 0 | $0 |
| Yale University | New Haven, CT | 46 | $49.9 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 36 | $48.5 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 42 | $48.4 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 38 | $44.2 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 31 | $43.4 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 35 | $38.9 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 25 | $38.4 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 5 | $38.3 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 20 | $34.6 million | 0 | $0 |
| University of Louisville | Louisville, KY | 28 | $34.1 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 11 | $32.1 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 31 | $31.7 million | 0 | $0 |
| Duke University | Durham, NC | 21 | $25.5 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 21 | $24.7 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 25 | $24.1 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 19 | $23.3 million | 0 | $0 |
| Washington University | Saint Louis, MO | 17 | $23 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 20 | $22.9 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 10 | $22.6 million | 0 | $0 |
| Emory University | Atlanta, GA | 27 | $22.5 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 17 | $22.3 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 8 | $21.6 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 22 | $21.3 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 12 | $18.9 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 10 | $18.1 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 22 | $18 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 12 | $17.3 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 20 | $16.9 million | 0 | $0 |
| University of Oklahoma HLTH Sciences CTR | Oklahoma City, OK | 13 | $15.9 million | 0 | $0 |
| North Carolina State University | Raleigh, NC | 6 | $15.9 million | 0 | $0 |
| Stanford University | Stanford, CA | 12 | $15.5 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 11 | $15.2 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 13 | $15.2 million | 0 | $0 |
| Oklahoma Medical Research Foundation | Oklahoma City, OK | 1 | $15.2 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 15 | $14.7 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 12 | $13.8 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 14 | $13 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 20 | $12.9 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 11 | $12.4 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 11 | $12.3 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 5 | $12.3 million | 0 | $0 |
| Rockefeller University | New York, NY | 7 | $11.8 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 4 | $11.2 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 7 | $11.1 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 8 | $10.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 11 | $10.8 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 10 | $10.4 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 9 | $9.6 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 7 | $9.2 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 8 | $8.8 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 6 | $8.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 6 | $8.7 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 8 | $8.6 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 7 | $8.3 million | 0 | $0 |
| University of Florida | Gainesville, FL | 8 | $8.1 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 11 | $7.6 million | 0 | $0 |
| Princeton University | Princeton, NJ | 4 | $7.3 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 7 | $7.3 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 6 | $7.1 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 9 | $7 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 3 | $7 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 6 | $6.8 million | 0 | $0 |
| Pharmain Corporation | Bothell, WA | 1 | $6.8 million | 0 | $0 |
| Mitopower LLC | Palo Alto, CA | 1 | $6.5 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 7 | $6.3 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 6 | $5.9 million | 0 | $0 |
| Northeast Ohio Medical University | Rootstown, OH | 8 | $5.7 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 5 | $5.6 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 3 | $5.6 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 6 | $5.5 million | 0 | $0 |
| Triad National Security, LLC | Los Alamos, NM | 2 | $5.5 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 5 | $5.4 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 2 | $5.3 million | 0 | $0 |
| Georgetown University | Washington, DC | 6 | $5.3 million | 0 | $0 |
| Ohio State University | Columbus, OH | 3 | $5.3 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 3 | $5.2 million | 0 | $0 |
| Wayne State University | Detroit, MI | 4 | $5.1 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 4 | $5 million | 0 | $0 |
| University of California at Davis | Davis, CA | 7 | $4.8 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 3 | $4.7 million | 0 | $0 |
| Boston Medical Center | Boston, MA | 4 | $4.7 million | 0 | $0 |
| Northern California Institute/res/edu | San Francisco, CA | 1 | $4.6 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 7 | $4.5 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 3 | $4.4 million | 0 | $0 |
| Imcare Biotech, Inc. | Doylestown, PA | 2 | $4.4 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 2 | $4.2 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 5 | $4.2 million | 0 | $0 |
| New York University | New York, NY | 2 | $4.1 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 3 | $4.1 million | 0 | $0 |
| Senseion Therapeutics, Inc. | Saint Louis, MO | 2 | $4 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 5 | $4 million | 0 | $0 |
| University of North Carolina Greensboro | Greensboro, NC | 3 | $4 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 3 | $3.9 million | 0 | $0 |
| George Washington University | Washington, DC | 4 | $3.9 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 6 | $3.8 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 732 | $409,117,807 | 0 | $0 |
| 2024 | 800 | $388,523,927 | 0 | $0 |
| 2023 | 814 | $386,148,696 | 0 | $0 |
| 2022 | 786 | $368,035,471 | 0 | $0 |
| 2021 | 758 | $344,881,177 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.